Vasculitis & polymyalgia rheumatica
Effect of vitamin D treatment in anti-neutrophil cytoplasm autoantibody (ANCA)-associated vasculitis: results from an exploratory perspective, pragmatic, non-randomised study
Study context
- Population
- Patients with AAV at the Vasculitis Clinic (Toronto, Canada), January to July 2021
- Participants
- 101 patients
- Comparison
- Low vs normal baseline vitamin D (25(OH)D); low-level patients asked to increase supplementation by 1000 IU/day
- Low vitamin Dn = 41
- Normal vitamin Dn = 60reference
- Primary endpoint
- Disease relapse
- Follow-up
- 12 months
Methodological detailspragmatic, exploratory, ITT and per-protocol analyses, single-centre
- Pragmatic
- Exploratory
- ITT and per-protocol analyses
- Single-centre
Primary result
As reported in the abstract
Relapse · month 12
P = 0.64
Further findings
- Normal 25(OH)D achieved at month 12 among low-vitamin D patients reassessed — Low vitamin D
- 62.5%
- Normal 25(OH)D achieved at month 12 among low-vitamin D patients reassessed: 32 had vitamin D level reassessed at month 12
Relapse in patients who corrected baseline vitamin D deficiency
- No relapses observed
Original publication
Effect of vitamin D treatment in ANCA-associated vasculitis: results from an exploratory perspective, pragmatic, non-randomised study. Clin Exp Rheumatol. Published 26 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →